Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL719464 | 0.98 | CYP4F2 (0.53) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 | |
| Ethylenediamine SCHEMBL3498869 | 0.86 | CYP4F2 (0.55) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 | |
| SCHEMBL444076 | 0.85 | CYP4F2 (0.63) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 | |
| SCHEMBL28231496 | 0.84 | CYP4F2 (0.63) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL49875 | 0.83 | CYP4F2 (0.61) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 | |
| SCHEMBL28872935 | 0.83 | CYP4F2 (0.61) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 | |
| SCHEMBL11001997 | 0.83 | CYP4F2 (0.61) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL27834192 | 0.82 | SOAT1 (0.50) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 | |
| SCHEMBL504042 | 0.82 | CYP4F2 (0.55) | CYP4F2CYP4A11ALOX15ALDH1A1LMNA | |
| Bromide SCHEMBL25233680 | 0.81 | CYP4F2 (0.59) | CYP4F2CYP4A11ALOX15ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4767757-A | Acyloxythiophene-carboxamide fungicides, compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-30 | — | — | US | claimed |
| EP-0241735-A2 | Acyloxythiophene carbon amide | BAYER AG (DE) | 1987-10-21 | — | — | EP | claimed |
| CN-1266118-C | Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides | NOVARTIS AG (CH) | 2006-07-26 | — | — | CN | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| CN-1550491-A | Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides | ��˹��ŵ�� | 2004-12-01 | — | — | CN | disclosed |
| CN-1153759-C | Novel delta-amino-gamma hydroxy-omega-aryl-alkanamides | ��˹��ŵ�� | 2004-06-16 | — | — | CN | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5955487-A | TREATING HIGH BLOOD PRESSURE, CARDIAC INSUFFICIENCY, GLAUCOMA | CIBA-GEIGY CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0287471-B1 | CARBOXYSTYRENE DERIVATIVES AND DRUGS CONTAINING THEM AS EFFECTIVE INGREDIENTS | MITSUBISHI KASEI CORPORATION (JP) | 1992-09-09 | — | — | EP | disclosed |
| US-4960768-A | Acyloxythiophene-carboxamide fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
| US-4925861-A | LEUKOTRIENE ANTAGONISTS, PHOSPHOLIPASE INHIBITORS | MITSUBISHI KASEI CORPORATION (JP) | 1990-05-15 | — | — | US | disclosed |
| US-4863954-A | Acyloxythiophene-carboxamide fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0287471-A2 | Carboxystyrene derivatives and drugs containing them as effective ingredients | MITSUBISHI KASEI CORPORATION (JP) | 1988-10-19 | — | — | EP | disclosed |
| US-4767757-A | Acyloxythiophene-carboxamide fungicides, compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1988-08-30 | — | — | US | disclosed |
| EP-0241735-A2 | Acyloxythiophene carbon amide | BAYER AG (DE) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | CYP4F2 2904/4885CYP4A11 705/4885ALOX15 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.